REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ("Coherus" or the "Company") (NASDAQ:CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company's common stock (the "Offering"). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The Offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.

Coherus intends to use the net proceeds from the Offering to support the ongoing commercialization of LOQTORZI® (toripalimab-tpzi), to continue clinical development of its product candidates, and for working capital and other general corporate purposes.

TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as the joint bookrunners for the Offering.

The securities described above are being offered by Coherus pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291520) that was previously filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2025. The Offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement and ...